Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25994598 | 0.83 | GRM2 (0.40) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL18863211 | 0.80 | GRM2 (0.50) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL24147834 | 0.79 | CLK4 (0.53) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL8170641 | 0.79 | CLK4 (0.37) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL12240961 | 0.77 | CLK4 (0.44) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL17141660 | 0.77 | CLK4 (0.46) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL3532428 | 0.76 | GRM2 (0.46) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL30004086 | 0.74 | GRM2 (0.42) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL27086356 | 0.74 | GRM2 (0.42) | GRM2PIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL1334382 | 0.74 | KDR (0.54) | GRM2PIK3CDPIK3CBPIK3CACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014075387-A1 | DIARYL HYDANTOIN DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海医药集团股份有限公司 (CN) | 2014-05-22 | — | — | WO | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| WO-2008079759-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F8, F9 | GRM2 4565/4885PIK3CD 3294/4885PIK3CB 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.